126 related articles for article (PubMed ID: 37583304)
1. Malignant mesothelioma cells with characteristic intracytoplasmic vacuolization and lipids.
Morito S; Yasui H; Itoh T; Kamoshida S; Ohsaki H
Diagn Cytopathol; 2023 Dec; 51(12):E328-E331. PubMed ID: 37583304
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of methylthioadenosine phosphorylase and BRCA-associated protein 1 immunohistochemistry in the diagnosis of malignant mesothelioma in effusion cytology specimens.
Berg KB; Churg AM; Cheung S; Dacic S
Cancer Cytopathol; 2020 Feb; 128(2):126-132. PubMed ID: 31821740
[TBL] [Abstract][Full Text] [Related]
3. Genomic-based ancillary assays offer improved diagnostic yield of effusion cytology with potential challenges in malignant pleural mesothelioma.
Kinoshita Y; Hamasaki M; Matsumoto S; Yoshimura M; Sato A; Tsujimura T; Kamei T; Kawahara K; Nabeshima K
Pathol Int; 2020 Sep; 70(9):671-679. PubMed ID: 32542810
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic value of BRCA1-associated protein-1, glucose transporter-1 and desmin expression in the discrimination between reactive mesothelial proliferation and malignant mesothelioma in tissues and effusions.
Önder S; Özogul E; Koksal D; Sarinc Ulasli S; Firat P; Emri S
Cytopathology; 2019 Nov; 30(6):592-600. PubMed ID: 31165505
[TBL] [Abstract][Full Text] [Related]
5. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
6. Lipid-rich diffuse malignant mesothelioma: a case report.
Chang HT; Yantiss RK; Nielsen GP; McKee GT; Mark EJ
Hum Pathol; 2000 Jul; 31(7):876-9. PubMed ID: 10923929
[TBL] [Abstract][Full Text] [Related]
7. Podoplanin is a useful marker for identifying mesothelioma in malignant effusions.
Hanna A; Pang Y; Bedrossian CW; Dejmek A; Michael CW
Diagn Cytopathol; 2010 Apr; 38(4):264-9. PubMed ID: 20146302
[TBL] [Abstract][Full Text] [Related]
8. Small orangiophilic squamous-like cells: an underrecognized and useful morphological feature for the diagnosis of malignant mesothelioma in pleural effusion cytology.
Chen L; Caldero SG; Gmitro S; Smith ML; De Petris G; Zarka MA
Cancer Cytopathol; 2014 Jan; 122(1):70-5. PubMed ID: 23983174
[TBL] [Abstract][Full Text] [Related]
9. Comparison of immunohistochemical mesothelial biomarkers in paired biopsies and effusion cytology cell blocks from pleural mesothelioma.
Mansour MSI; Huseinzade A; Seidal T; Hejny K; Maty A; Taheri-Eilagh F; Mager U; Dejmek A; Dobra K; Brunnström H
Cytopathology; 2023 Sep; 34(5):456-465. PubMed ID: 37337638
[TBL] [Abstract][Full Text] [Related]
10. A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
Kinoshita Y; Hida T; Hamasaki M; Matsumoto S; Sato A; Tsujimura T; Kawahara K; Hiroshima K; Oda Y; Nabeshima K
Cancer Cytopathol; 2018 Jan; 126(1):54-63. PubMed ID: 29053210
[TBL] [Abstract][Full Text] [Related]
11. Cytological Assessment of Desmoplastic Malignant Pleural Mesothelioma in an Autopsy Case.
Kawamoto Y; Kure S; Katayama H; Kawahara K; Teduka K; Kunugi S; Onda M; Motoda N; Ohashi R
J Nippon Med Sch; 2023 Feb; 89(6):616-622. PubMed ID: 34840219
[TBL] [Abstract][Full Text] [Related]
12. Immunocytochemistry of CD146 is useful to discriminate between malignant pleural mesothelioma and reactive mesothelium.
Sato A; Torii I; Okamura Y; Yamamoto T; Nishigami T; Kataoka TR; Song M; Hasegawa S; Nakano T; Kamei T; Tsujimura T
Mod Pathol; 2010 Nov; 23(11):1458-66. PubMed ID: 20657552
[TBL] [Abstract][Full Text] [Related]
13. Effusion cytology of pleural mesothelioma, epithelial type, with extreme cytoplasmic vacuolization.
Akin MR; Nguyen GK
Acta Cytol; 2004; 48(3):469-71. PubMed ID: 15192978
[No Abstract] [Full Text] [Related]
14. The cytological features of effusions with mesothelioma in situ: A report of 9 cases.
Michael CW; Bedrossian CCWM; Sadri N; Klebe S
Diagn Cytopathol; 2023 Jun; 51(6):374-388. PubMed ID: 36942732
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic mesothelioma biomarkers in effusion cytology.
Eccher A; Girolami I; Lucenteforte E; Troncone G; Scarpa A; Pantanowitz L
Cancer Cytopathol; 2021 Jul; 129(7):506-516. PubMed ID: 33465294
[TBL] [Abstract][Full Text] [Related]
16. IMP3/L523S, a novel immunocytochemical marker that distinguishes benign and malignant cells: the expression profiles of IMP3/L523S in effusion cytology.
Ikeda K; Tate G; Suzuki T; Kitamura T; Mitsuya T
Hum Pathol; 2010 May; 41(5):745-50. PubMed ID: 20060157
[TBL] [Abstract][Full Text] [Related]
17. Utility of anti-L523S antibody in the diagnosis of benign and malignant serous effusions.
Hanley KZ; Facik MS; Bourne PA; Yang Q; Spaulding BO; Bonfiglio TA; Xu H
Cancer; 2008 Feb; 114(1):49-56. PubMed ID: 18098206
[TBL] [Abstract][Full Text] [Related]
18. Morphology of 9p21 homozygous deletion-positive pleural mesothelioma cells analyzed using fluorescence in situ hybridization and virtual microscope system in effusion cytology.
Matsumoto S; Nabeshima K; Kamei T; Hiroshima K; Kawahara K; Hata S; Marukawa K; Matsuno Y; Taguchi K; Tsujimura T
Cancer Cytopathol; 2013 Aug; 121(8):415-22. PubMed ID: 23450849
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic Accuracy of a Limited Immuno-panel of Calretinin and Ber-EP4 for Diagnosis of Malignant Effusions.
Khurram N; Anis T; Yusuf NW
J Coll Physicians Surg Pak; 2019 Jan; 29(1):33-36. PubMed ID: 30630566
[TBL] [Abstract][Full Text] [Related]
20. Determination of PD-L1 expression in effusions from mesothelioma by immuno-cytochemical staining.
Mansour MSI; Seidal T; Mager U; Baigi A; Dobra K; Dejmek A
Cancer Cytopathol; 2017 Dec; 125(12):908-917. PubMed ID: 28922567
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
